Q1 2026 earnings call: ficera trial updates, FDA-guided dosing study, cash runway and 2027 catalysts—read key takeaways now.

The primary endpoint in the study was PFS from time of randomization until death or disease progression as assessed by an investigator, with the goal of the study demonstrating a HR of 0.6. In the ...

The CIRCULATE Spain study: Circulating tumor DNA based decision for adjuvant treatment in localized colon cancer. PACE: A phase III trial of CAPOX versus anti-PD-1 inhibitor as adjuvant therapy for ...